Atlas Trials

Ming-Yuan Chen

12 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Ming-Yuan Chen

RecordFirmDate
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases (NCT07481799)Ming-Yuan Chen2026-02-06
Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT07524452)Ming-Yuan Chen2026-02-06
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma (NCT07328854)Ming-Yuan Chen2025-11-20
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy (NCT07328841)Ming-Yuan Chen2025-11-18
Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT07581821)Ming-Yuan Chen2025-09-15
Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer (NCT07188584)Ming-Yuan Chen2025-08-20
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial (NCT07070479)Ming-Yuan Chen2025-06-24
Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas (NCT06870435)Ming-Yuan Chen2025-01-24
"Xijiang Project" Screening Cohort for NPC (NCT06787456)Ming-Yuan Chen2024-11-14
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC (NCT06472713)Ming-Yuan Chen2024-07-20
Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma (NCT06688760)Ming-Yuan Chen2023-11-01
Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma. (NCT06529562)Ming-Yuan Chen2022-11-01

Track Ming-Yuan Chen automatically

Every clearance here is in the API, with alerts when new ones post.